---
title: "Cerenome Reports Second Quarter 2026 Financial Results and Business Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295973378.md"
description: "Cerenome reported Q2 2026 results, showing an operating loss of $9.1 million and net loss of $9.0 million, compared to a net income in Q2 2025. Cash reserves stood at $8.6 million. The company rebranded from Plus Therapeutics and highlighted progress in REYOBIQ clinical trials and CNSide assay commercialization, including expanded payer coverage and AI partnerships."
datetime: "2026-08-14T20:17:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295973378.md)
  - [en](https://longbridge.com/en/news/295973378.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295973378.md)
generator: "portal-rs"
---

# Cerenome Reports Second Quarter 2026 Financial Results and Business Update

Cerenome, Inc. (Nasdaq: CNSY), a CNS oncology company based in Houston, released its financial results for the second quarter of 2026, ending on June 30. The Company focuses on precision diagnostics, targeted therapeutics, and artificial intelligence in the field. Cerenome provided insights into recent business developments and upcoming highlights along with this announcement.

### Related Stocks

- [PSTV.US](https://longbridge.com/en/quote/PSTV.US.md)
- [CNSY.US](https://longbridge.com/en/quote/CNSY.US.md)

## Related News & Research

- [Plus Therapeutics GAAP EPS of -$1.31 misses by $0.45; reaffirms FY outlook](https://longbridge.com/en/news/296058426.md)
- [Cerenome Launches as an Integrated CNS Oncology Company | PSTV Stock News](https://longbridge.com/en/news/294514925.md)
- [LIFE: Cost base reduced, cash runway extended, and regulatory focus sharpened for pivotal CE study](https://longbridge.com/en/news/296326254.md)
- [Valens Semiconductor CFO Karine Pinto Flomenboim files initial beneficial ownership statement](https://longbridge.com/en/news/296365335.md)
- [Plus Therapeutics amends bylaws to reflect corporate name change to Cerenome](https://longbridge.com/en/news/294876172.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**